

**Types of Articles Considered for Publication by  
the *Egyptian Journal of Hypertension & Cardiovascular Risk***

**ORIGINAL RESEARCH:**

- **Original Articles** are scientific reports of the results of original clinical research. They should be no longer than 5000 words including an abstract.
- **Special Articles** include data and generally focus on areas such as economics, ethics, law, or health care delivery. They are limited to the same word count as original articles.

**CLINICAL CASES:**

- **Brief Reports** usually describe one to three patients or a single family and should be no longer than 2000 words. They do not include an abstract.

**REVIEW ARTICLES:**

Review articles are usually solicited by the editors, but we are willing to consider unsolicited material. Please contact the editorial office before writing a review article for the journal. All review articles undergo the same peer-review and editorial process as original research reports. They should be written for the general physician, not specialists.

**Conflicts of Interest:** Because the essence of review articles and editorials is selection and interpretation of the literature, the journal expects that the authors of such articles will not have any financial associations with a company (or its competitors) that makes a product discussed in the article.

Review articles also include:

- **Current Concepts** articles focus on clinical topics, including those in specialty areas but of wide interest. The text is limited to 2000 words, with a maximum of four figures and tables plus up to 50 references.
- **Drug Therapy** articles detail the pharmacology and use of specific drugs or classes of drugs, or the various drugs used to treat particular diseases. There is a limit of 4000 words.
- **Issues in Clinical Practice** articles are evidence-based reviews of topics relevant to practicing physicians, both primary care providers and specialists. Articles in this series should be no longer than 2500 words and should include the following sections: clinical context, strategies and evidence, areas of uncertainty, guidelines from professional societies, and recommendations from author(s).

- **Mechanisms of Disease** articles discuss the cellular and molecular mechanisms of diseases or categories of diseases. The text is limited to 4000 words.
- **Medical Progress** articles provides comprehensive, overviews of important clinical subjects, with the principal focus on developments during the past few years. Each article details how the perception of a disease, diagnostic approach, or therapeutic intervention has evolved in recent years. The text is limited to 4000 words, with a maximum of six tables and figures.

**OTHER SUBMISSIONS:**

- **Clinical Implications of Basic Research** articles discuss papers from preclinical journals. The purpose is to explain the findings and comment on their possible clinical applications in fewer than 1000 words.
- **Occasional Notes** are accounts of personal experiences or descriptions of material from outside the usual areas of medical research and analysis.

## **INSTRUCTIONS FOR SUBMISSION**

These guidelines are in accordance with the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” (originally published in N Engl J Med 1997;336:309-15).

### **MANUSCRIPTS**

#### **TITLES AND AUTHORS' NAMES**

With the manuscript, provide a page giving the title of the paper; titles should be concise and descriptive. Also include a running head of fewer than 40 letter spaces; the name(s) of the author(s), including the first name(s) and no more than two degrees; the name of the department and institution in which the work was done; the institutional affiliation of each author; and the name and address of the author to whom reprint requests should be addressed. Any grant support that requires acknowledgment should be mentioned on this page. Front page should include the following:

- Title
- Author's name(s)
- Institution(s)
- Grant support
- Authors correspondence (mailing address, telephone, fax, mobile, e-mail)
- Word count

#### **ABSTRACTS**

Provide on a separate page an abstract of not more than 250 words. This abstract should consist of five paragraphs, labeled Background, Aims, Methods, Results, and Conclusions. They should briefly describe the problem being addressed in the study, how the study was performed, the salient results, and what the authors conclude from the results.

#### **KEY WORDS**

Three to 10 key words or short phrases should be added to the bottom of the abstract page; these will help us index the article and may be published with the Abstract. We encourage the use of terms from the Medical Subject Headings from Index Medicus.

#### **MATERIAL & METHODS**

**MATERIAL:** Describe how the patient population is derived.

**METHODS:** Describe how the study procedures are performed. Give details of instruments, materials and procedures followed. If these are previously published, it is sufficient to cite the reference.

## **RESULTS**

Describe the main findings and the analytical methods used as well as the findings from data analysis. Data provided in text, tables and figures should be enough to support the conclusion.

## **DISCUSSION**

Authors may elaborate on context, implications and concordance or otherwise with previously published observations.

## **REFERENCES**

References must be numbered consecutively as they are cited. The style of references is that of Index Medicus. List all authors when there are six or fewer; when there are seven or more, list the first three, then "et al." The following is a sample reference:

1. Lahita R, Kluger J, Drayer DE, Koffler D, Reidenberg MM. Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide. *N Engl J Med* 1979;301:1382-5.

Numbered references to personal communications, unpublished data, and manuscripts either "in preparation" or "submitted for publication" are unacceptable. If essential, such material may be incorporated in the appropriate place in the text.

## **TABLES**

Double-space tables and provide a title for each.

## **ILLUSTRATIONS**

Figures should be clear and legible. Diagrams are preferred in one or two colors. Glossy photographs are requested. Symbols, lettering, and numbering should be clear and large enough to remain legible after the figure has been reduced to fit in the space allocated to it.

The back of each figure should include the sequence number, the name of the author, and the proper orientation (e.g., "top"). Do not mount the figure on cardboard. Photomicrographs and electron photomicrographs should have internal scale markers.

If photographs of patients are used, the subjects should not be identifiable.

Legends for illustrations should be double-spaced on a separate sheet and should not appear on the illustrations.

Color illustrations are accepted at a small additional cost. Send both transparencies (or negatives) and prints for this purpose.

## **ABBREVIATIONS**

Except for units of measurement, abbreviations are generally discouraged. The first time an abbreviation appears it should be preceded by the words for which it stands.

## **DRUG NAMES**

Generic names should generally be used. When proprietary brands are used in research, include the brand name in parentheses in the Methods section.

## **AUTHORSHIP AND CONTRIBUTORSHIP**

### **Contributorship**

We list contributors in two ways. Firstly, we publish a list of authors' names at the beginning of the paper and, secondly, we list contributors at the end of the paper, giving details of who did what in planning, conducting, and reporting the work.

One or more of these contributors are listed as guarantors of the paper. Guarantor status does mean that he or she is prepared to take public responsibility for the paper as a whole.

### **Authorship**

The uniform requirements for manuscripts submitted to medical journals state that authorship credit should be based only on substantial contribution to:

- conception and design, or analysis and interpretation of data
- drafting the article or revising it critically for important intellectual content

## **REVIEW AND ACTION**

Manuscripts are examined by the editorial staff and are usually sent to outside reviewers. We encourage authors to suggest the names of possible reviewers, but we reserve the right of final selection. Letters about potentially acceptable manuscripts will be sent after the review process is complete. For information about the status of a submitted manuscript, call telephone number (202) 794-7788, at least 3 weeks after date of submission.

## **CONFLICT OF INTEREST**

Authors of research articles should disclose at the time of submission any financial arrangement they may have with a company whose product is used prominently in the study or with a company making a competing product. Such information will be confidential and will not influence the editorial decision, but if the article is accepted for publication, such information is to be communicated to the reader.

## **COPYRIGHT**

Authors agree to copyright-transfer as requested. Copyright in any contribution is owned by the Egyptian Hypertension Society. The Society has the right to use, publish, and distribute the contribution, in the journal.

## **SIZE OF THE MANUSCRIPT**

Original contributions should not exceed 5000 words including title and reference pages, tables and figure legends. Please provide word count. All manuscripts must be typed in double-space, font 12 with 1" margins.

## **LETTERS TO THE EDITOR**

Letters to the Editor are considered for publication provided they do not contain material that has been submitted or published elsewhere.

Please note the following:

- Your letter must be type written and double-spaced.
- Its text, not including references, must not exceed 400 words (please provide word count).
- It must have no more than five references and one figure or table.
- It must not be signed by more than three authors.
- Please include your full address, telephone number, fax number, and e-mail address.
- Financial associations or other possible conflicts of interest must be disclosed.

You may send us your letter by standard mail, fax or e-mail.

Our Contact information:

Letters to the Editor, The Egyptian Journal of Hypertension & Cardiovascular Risk,  
1 El-Diwan Street,

Garden City, 11519, Cairo - Egypt

Phone: (202) 794-8877;

Fax: (202) 794-8879;

E-mail: [ehs@link.net](mailto:ehs@link.net)

## **SUBMITTING MATERIAL ON DISK**

If your article has been accepted for publication please also submit it (in its revised form, if revisions have been made) on disk.

Our preferred disk format is a file in Word (MS Windows 98/2000) on a 3.5" disk.

**Articles on disk should be prepared in the simplest form**

- Label your disk with:
  - the number of the paper
  - its title
  - name of the first author
  - the word processing program and version used
  - the filename(s) to be found on the disk.
  - Number the pages of each hard copy by hand.
- Finally, check the final copy carefully; if there are differences between the hard copy and disk version we will use the disk version as the master.

**RELEASE OF MATERIAL TO THE MEDIA**

We do not want material that is published in the Egyptian Journal of Hypertension & Cardiovascular Risk appearing beforehand, in detail, in the mass media. We accept that reports may appear in the media after presentations at scientific meetings.

Those authors who wish us to publish their papers can clarify matters for journalists, but should not give the media any further information than was included in their scientific presentations.